Inspired by the emerging studies in the field of allergy, the BAT was developed as one of the experimental assays to be applied alongside several clinical assays for the prediction and monitoring of the potential for anaphylaxis with IgE immunotherapy for the first-in-class IgE in oncology [97,115]. This evidence concerns the gene IGHE and allergic disease.